Abstract Number: 0397 • ACR Convergence 2024
Trends in New Use of Disease-Modifying Antirheumatic Drugs in Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001-2022
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disorder. An increasing array of disease-modifying antirheumatic drugs (DMARDs) have become available to treat…Abstract Number: 0452 • ACR Convergence 2024
Reproductive Health Needs of Women with Rheumatic Disease: An EMR-Based Online Survey Study
Background/Purpose: Reproductive-aged women are disproportionately affected by rheumatologic disorders, making family planning issues like contraception, pre-conception counseling, fertility, pregnancy complications, and postpartum care critical components…Abstract Number: 0398 • ACR Convergence 2024
Validation of Patient-Reported Outcomes Measurement Information System® (PROMIS®) Pediatric Measures for Children with Chronic Nonbacterial Osteomyelitis Using the CHOIR Data
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease. It is critical to capture the child’s health-related quality of life impact using validated patient-reported…Abstract Number: 0446 • ACR Convergence 2024
Rheum for Improvement: Contraception Counseling and Adherence in Patients with Lupus and Rheumatoid Arthritis on Teratogenic Medications
Background/Purpose: Methotrexate (MTX) and mycophenolate (MMF) are two common medications for both lupus (SLE) and rheumatoid arthritis (RA). Both medications are contraindicated in pregnancy, necessitating…Abstract Number: 0394 • ACR Convergence 2024
Unveiling Major Challenges and Unmet Needs in the Therapeutic Approach to Systemic Juvenile Idiopathic Arthritis: The Patient Perspective
Background/Purpose: Despite continuous improvements in the therapeutic options for children with systemic juvenile idiopathic arthritis (sJIA), access to medications significantly differs among centres and countries.…Abstract Number: 0487 • ACR Convergence 2024
The Triglyceride to HDL Ratio, a Surrogate Marker of Insulin Resistance, Predicts All Cause and Cardiovascular Mortality in Rheumatoid Arthritis
Background/Purpose: The triglyceride to HDL cholesterol (TG/HDL) ratio, a recognized surrogate marker of insulin resistance, has emerged as a predictor of cardiovascular (CV) risk. However,…Abstract Number: 0466 • ACR Convergence 2024
Inpatient Outcomes of Rheumatoid Arthritis in Hospitalized Patients Using Cannabis: Data from the National Inpatient Sample
Background/Purpose: Despite advancements in rheumatoid arthritis (RA) treatment, effective pain management remains challenging, with many patients also experiencing insomnia, anxiety, and depression. As cannabis legalization…Abstract Number: 0478 • ACR Convergence 2024
Skin Sodium in Patients with Rheumatoid Arthritis: Association with Blood Pressure and Disease Activity
Background/Purpose: Sodium is stored in tissues such as the skin where it may contribute to development and progression of autoimmune diseases and hypertension through activation…Abstract Number: 2518 • ACR Convergence 2024
Behçet’s Disease Immune Landscape Exhibits a Universal NF-kB-mediated Hyperactivation Pattern with Cell-specific TNFAIP3 Responses and a Superimposed IFN-regulated Endotype
Background/Purpose: The immune landscape of Behçet’s disease (BD) remains ill-defined, lacking a unifying picture, precise disease phenotype-endotype correlations, and an understanding of immunity at target…Abstract Number: 0386 • ACR Convergence 2024
Variability of Data Completeness and Consensus Treatment Plan Adherence for Polyarticular Juvenile Idiopathic Arthritis Patients Within the Childhood Arthritis and Rheumatology Research Alliance Registry
Background/Purpose: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry is a large observational registry of children and young adults with childhood-onset rheumatic disease. The Registry is…Abstract Number: 0399 • ACR Convergence 2024
Eosinophilia and Exposure to IL-1 and IL-6 Blocking Biologic Medications in a Systemic Juvenile Idiopathic Arthritis Patient Cohort
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a severe disease with symptoms of fevers, rash, and arthritis. High levels of the inflammatory cytokines interlukin-1 (IL-1)…Abstract Number: 2551 • ACR Convergence 2024
Modified Delphi Process to Propose an Equity Measurement Roadmap in Rheumatology
Background/Purpose: Achieving health equity has been a long-standing goal, as Academy of Medicine leaders stated, ‘There is no equity without quality, and there is no…Abstract Number: 0479 • ACR Convergence 2024
Constructing and Using a Novel Nucleotide Transformer for Patients with Rheumatoid Arthritis
Background/Purpose: Applying the methods of artificial intelligence (AI) to genomic data for clinical outcome prediction in rheumatoid arthritis (RA) is an area of growing research.…Abstract Number: 2519 • ACR Convergence 2024
What Do We Know About Malignancies in IgA Vasculitis?
Background/Purpose: Cancer has been reported as a potential trigger of IgA vasculitis (IgAV) in adults, however data on this topic is scarce. The aim of…Abstract Number: 0468 • ACR Convergence 2024
Plasma Calprotectin Assessed in Multiple Biological Treatment Strategies for Early Rheumatoid Arthritis over 48 Weeks
Background/Purpose: Plasma calprotectin is a sensitive biomarker of inflammation in patients with rheumatoid arthritis (RA) and reflects activation of granulocytes and macrophages. Calprotectin has not…
- « Previous Page
- 1
- …
- 239
- 240
- 241
- 242
- 243
- …
- 2607
- Next Page »
